GAIA GROW CORP.
Gaia Grow Corp., through its subsidiaries, operates as an integrated licensed hemp company. It is also licensed for cannabis and hemp processing, extraction, product formulation, novel product development, and cannabis retail businesses. The company is based in Vancouver, Canada.
GAIA GROW CORP. (GG00) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GAIA GROW CORP. (GG00) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GAIA GROW CORP. - Net Assets Trend (None–None)
This chart illustrates how GAIA GROW CORP.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GAIA GROW CORP. (None–None)
The table below shows the annual net assets of GAIA GROW CORP. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GAIA GROW CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GAIA GROW CORP. Competitors by Market Cap
The table below lists competitors of GAIA GROW CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADVANCED INF SERV(ADVANC)
STU:NVAA
|
$96.87K |
|
DAINIP S'TOMO PHARM - Dusseldorf Stock Exchang
DU:DPM
|
$96.87K |
|
NORSK SOLAR AS NK -01
F:62L
|
$96.88K |
|
M.P.Evans Group
LSE:MPE
|
$96.93K |
|
NAMPAK LTD RC-05
F:NNZA
|
$96.80K |
|
Galata Acquisition Corp. II Class A Ordinary Shares
NASDAQ:LATA
|
$96.79K |
|
REMEGEN CO. LTD YC 1
F:REG
|
$96.68K |
|
Allmed Solutions Ltd
TA:ALMD
|
$96.61K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GAIA GROW CORP.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GAIA GROW CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GAIA GROW CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GAIA GROW CORP.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GAIA GROW CORP. (GG00) | €- | N/A | N/A | $96.82K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |